Format

Send to

Choose Destination
Ecancermedicalscience. 2017 Nov 30;11:787. doi: 10.3332/ecancer.2017.787. eCollection 2017.

Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come.

Author information

1
Humanitas Research Hospital, Medical Oncology, Via Manzoni 56, 20089 Rozzano, Italy.

Abstract

Diagnostic and treatment algorithms in non-small cell lung cancer (NSCLC) are evolving at a never-before-seen pace. Histological subtyping to maximise treatment efficacy and avoid toxicity has marked the beginning of the revolution, opening the way to molecular characterisation to guide genomically driven treatments with targeted agents, led by Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) inhibitors. More recently, agents against the Program Death 1 receptor (PD-1) and ligand 1 (PD-L1) have entered the clinical arena, offering new hope to NSCLC patients, although several uncertainties remain to be elucidated. Here, we review the most clinically relevant advances in the diagnosis and treatment of NSCLC in the past decade.

KEYWORDS:

anaplastic lymphoma kinase (ALK); checkpoint inhibitors; epidermal growth factor receptor (EGFR); non-small cell lung cancer (NSCLC); program death 1 receptor (PD-1)

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center